Recombitant α2b-Interferon in the Management of Myelodysplastic Syndromes

  • S. M. Donohue
  • S. Lim
  • B. J. Boughton
Conference paper

Abstract

Interferon treatment is effective in hairy cell and chronic granulocytic leukaemia although the exact mechanism of its antileukaemic action is uncertain. Since its cytoreductive, differentiation and immunoregulatory effects are potentially useful in myelodysplastic syndromes (MDS), a therapeutic study was undertaken on this condition.

Keywords

Lymphoma Interferon Thrombocytopenia Cytosine Weinstein 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bennett TM, Catovsky D, Daniel MT et al. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199PubMedGoogle Scholar
  2. 2.
    Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic states — a scoring system with prognostic significance. Br J Haematol 59: 425–433PubMedCrossRefGoogle Scholar
  3. 3.
    Herberman RB, Ortaloo JR, Mantovani A et al. (1982) Effect of human recombinant interferon on cytotoxic activity of natural killer ( NK) cells and monocytes. Cell Immunol 67: 160–167Google Scholar
  4. 4.
    Grant S, Bhalla K, Weinstein IB et al. (1982) Differential effect of recombinant human leucocyte interferon on human leukaemic and normal myeloid progenitor cells. Biochem Biophys Res Commun 108: 1048–1055PubMedCrossRefGoogle Scholar
  5. 5.
    Quesada JR, Reuben J, Manning JT, Harsh EM, Gutterman JU (1984) Alpha interferon for induction of remission in hairy-cell leukaemia. N Engl J Med 310: 15–18PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • S. M. Donohue
  • S. Lim
  • B. J. Boughton

There are no affiliations available

Personalised recommendations